Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-16-022838
Filing Date
2016-08-05
Accepted
2016-08-05 06:11:54
Documents
50
Period of Report
2016-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q fprx-10q_20160630.htm 10-Q 1492718
2 EX-10.1 fprx-ex101_379.htm EX-10.1 70316
3 EX-31.1 fprx-ex311_8.htm EX-31.1 8505
4 EX-31.2 fprx-ex312_7.htm EX-31.2 8501
5 EX-32.1 fprx-ex321_6.htm EX-32.1 5343
6 EX-32.2 fprx-ex322_9.htm EX-32.2 5236
7 GRAPHIC gph34p5gc3kt000001.jpg GRAPHIC 33971
  Complete submission text file 0001564590-16-022838.txt   4754325

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE DOCUMENT fprx-20160630.xml EX-101.INS 990070
9 XBRL TAXONOMY EXTENSION SCHEMA fprx-20160630.xsd EX-101.SCH 28930
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fprx-20160630_cal.xml EX-101.CAL 41643
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fprx-20160630_def.xml EX-101.DEF 82269
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE fprx-20160630_lab.xml EX-101.LAB 248035
13 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fprx-20160630_pre.xml EX-101.PRE 179667
Mailing Address TWO CORPORATE DRIVE SOUTH SAN FRANCISCO CA 94080
Business Address TWO CORPORATE DRIVE SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS INC (Filer) CIK: 0001175505 (see all company filings)

EIN.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36070 | Film No.: 161809020
SIC: 2834 Pharmaceutical Preparations